DIEMKIEU PHAM: Open Payments
NPI 1780259192 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 47 payments from 17 companies in 2025. Trend: 2023 $641 · 2024 $638 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $166 |
| ABBVIE INC. | 10 | $148 |
| Lilly USA, LLC | 7 | $127 |
| AstraZeneca Pharmaceuticals LP | 6 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $75 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: Ozempic, MOUNJARO, CAPLYTA, JARDIANCE, UBRELVY, AIRSUPRA, QULIPTA, REXULTI.
Industry payments across KS — which companies pay providers there.
